Eli Lilly rushes to FDA with its COVID-19 antibody for emergency green light, reveals new cocktail therapy data

Eli Lilly is hustling to the FDA with its antibody therapy for a speedy emergency use authorization (EUA) as it also reveals new data for a combo therapy.

Lilly said that it has now submitted an initial request for EUA for LY-CoV555 on its own, specifically in higher-risk patients who have been recently diagnosed with mild to moderate COVID-19. It will wait until November to ask for a EUA on the new cocktail therapy.